Clinical Outcomes of Perioperative Immunotherapy in Resectable Non–Small Cell Lung Cancer
This retrospective cohort study found that chemoimmunotherapy was associated with favorable clinical DMFS outcomes in patients with resectable NSCLC. The findings highlight the need to address barriers to broader adoption of chemoimmunotherapy.
Authors
- Ticiana A.B. Leal (ORCID: https://orcid.org/0000-0002-3735-9063)
- Erin Fidyk (ORCID: https://orcid.org/0000-0002-5592-1507)
- Aaron B. Cohen (ORCID: https://orcid.org/0000-0002-5598-9210)
- Jonathan Bryan
- Katherine Harrison (ORCID: https://orcid.org/0000-0002-2222-0261)
- Emily Castellanos (ORCID: https://orcid.org/0000-0003-4391-0496)
- Catherine Keane
- George Ho (ORCID: https://orcid.org/0000-0002-7352-9314)
- Laurynas Kalesinskas (ORCID: https://orcid.org/0000-0002-2903-2378)
- Karen Schwed
- Aakash Desai (ORCID: https://orcid.org/0000-0002-2943-3817)
- Qianyu Yuan (ORCID: https://orcid.org/0009-0001-4731-0263)
- A Marinescu
Institutions
- Fox Chase Cancer Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Emory University (US)
- University of Alabama at Birmingham (US)
- Flatiron Health (United States) (US)
- New York University (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.17953
- Citations
- 4
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- LUNGevity Foundation
- Flatiron Health